A Randomized, Double-Blind, Study to Explore the Efficacy and Safety of RE-021 in Focal Segmental Glomerulosclerosis (FONT-3)
This study is not yet open for participant recruitment.
Verified July 2012 by Retrophin, LLC.
Sponsor:
Retrophin, LLC.
Information provided by (Responsible Party):
Retrophin, LLC.
ClinicalTrials.gov Identifier:
NCT01613118
First received: June 4, 2012
Last updated: July 24, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |